1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26‑year follow‑up of the Framingham population. Am Heart J 1986; 111: 383–390.
2. von Eckardstein A, Wu FC. Androgens and coronary artery disease. Endocr Rev 2003; 24: 183–217.
3. Blahoš J, Bleha O. Endokrinologie. 2. vyd. Praha: Avicenum 1988.
4. Kreze A, Langer P, Klimeš I et al. Všeobecná a klinická endokrinológia. Bratislava: Academic Electronic Press 2004: 423–429.
5. Horwitz KB, Horwitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins and glucocorticoids. J Clin Invest 1982; 69: 750–758.
6. Hanke H, Lenz C, Hess B et al. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 2001; 103: 1382–1385.
7. Fujimoto R, Morimoto I, Morita E et al. Androgen receptors, 5 alfa‑reductase activity and androgen dependent proliferation of vascular smooth muscle cells. J Steroid Biochem Mol Biol 1994; 50: 169–174.
8. Cutolo M, Villaggio B, Barone A et al. Primary cultures of human synovial macrophages metabolize androgens. Ann N Y Acad Sci 1996; 784: 534–541.
9. Khetawat G, Faraday N, Nealen ML et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95: 2289–2296.
10. Kahn SM, Hryb DJ, Nakhla AM et al. Sex hormone binding globulin is synthesized in target cells. J Endocrinol 2001; 175: 113–120.
11. Hammes A, Andreassen TK, Spoelgen R et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122: 751–762.
12. Akishita M, Hashimoto M, Ohike Y et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res 2007; 30: 1029–1034.
13. Yue P, Chatterjee K, Beale C et al. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995; 91: 1154–1160.
14. Zitzmann M, Brune M, Kornmann B et al. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 2001; 86: 4867–4873.
15. Foresta C, Zuccarello D, De Toni L at al. Androgens stimulate endothelial progenitor cells through an androgen-mediated pathway. Clin Endocrinol (Oxf) 2008; 68: 284–289.
16. Foresta C, Caretta N, Lana A et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 2006; 91: 4599–4602.
17. Fu L, Gao QP, Shen JX. Relationship between testosterone and indexes indicating endothelial function in male coronary heart disease patients. Asian J Androl 2008; 10: 214–218.
18. Malkin CJ, Pugh PJ, Jones TH et al. Testosterone for secondary prevention in men with ischaemic heart disease? QJM 2003; 96: 521–529.
19. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet tromboxane A2 receptor density and aggregation responses. Circulation 1995; 91: 2742–2747.
20. Kupelian V, Page ST, Araujo AB et al. Low sex hormone‑binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843–850.
21. Araujo AB, Kupelian V, Page ST et al. Sex steroids and all cause and specific mortality in men. Arch Intern Med 2007; 167: 1252–1260.
22. Stellato RK, Feldman HA, Hamdy O et al. Testosterone, SHBG and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490–494.
23. Kupelian V, Hayes FJ, Link CL et al. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic group. J Clin Endocrinol Metab 2008; 93: 3403–3410.
24. Muller M, Grobbee DE, den Tonkelaar I et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618–2623.
25. Chubb SA, Hyde Z, Almeida OP et al. Lower sex hormone binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the health in men study. Eur J Endocrinol 2008; 158: 785–792.
26. Laaksonen DE, Nikanen L, Punnonen K et al. Testosterone and SHBG predict the metabolic syndrome and diabetes in middle aged men. Diabetes Care 2004; 27: 1036–1041.
27. Haffner SM, Valdez RA, Mykkänen L et al. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994; 43: 599–603.
28. Laaksonen DE, Niskanen L, Punnonen K et al. Sex hormones, inflammation and the metabolic syndrome: a population‑based study. Eur J Endocrinol 2003; 149: 601–608.
29. Haffner SM, Mykkänen L, Valdez RA et al. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77: 1610–1615.
30. Keating NL, O‘Malley AJ, Freedland SJ. Diabetes and cardiovascular disease during androgen deprivation: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39–46.
31. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non‑insulin‑dependent diabetes mellitus. Ann Intern Med 1992; 117: 807–811.
32. Andersson B, Mårin P, Lissner L et al. Testosterone concentration in women and men with NIDDM. Diabetes Care 1994; 17: 405–411.
33. Fukui M, Soh J, Tanaka M et al. Low serum testosterone concentration in middle-aged men with type 2 diabetes. Endocr J 2007; 54: 871–877.
34. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68–75.
35. Vikan T, Schirmer H, Njølstad I et al. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø study. Eur J Endocrinol 2009; 161: 435–442.
36. Tivesten A, Vandenput L, Labrie F et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94: 2482–2488.
37. Smith GD, Ben-Shlomo Y, Beswick A et al. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Cearphilly study. Circulation 2005; 112: 332–340.
38. Yeap BB, Hyde Z, Almeida OP et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94: 2353–2359.
39. Willnow TE, Hilpert J, Armstrong SA et al. Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci USA 1996; 93: 8460–8464.
40. Rosner W, Hryb DJ, Kahn SM et al. Interactions of sex hormone‑binding globulin with target cells. Mol Cell Endocrinol 2010; 316: 79–85.
41. Swerdlow AJ, Higgins CD, Schoemaker MJ et al. Mortality in patients with Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab 2005; 90: 6516–6522.
42. Bojesen A, Juul S, Birkebaek NH et al. Morbidity in Klinefelter syndrome, a Danish register study based on hospital discharge diagnoses. J Clin Endocrinol Metab 2006; 91: 1254–1260.
43. Bojesen A, Juul S, Birkebaek N et al. Increased mortality in Klinefelter syndrome. J Clin Endocrinol Metab 2004; 89: 3830–3834.
44. Kang SM, Jang Y, Kim JY et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 2002; 89: 862–864.
45. Lu YL, Kuang L, Zhu H et al. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5‑alpha-reductase inhibitor. Asian J Androl 2007; 9: 843–847.
46. English KM, Steeds RP, Jones TH et al. Low‑dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double‑blind, placebo-controlled study. Circulation 2000; 102: 1906–1911.
47. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003; 24: 909–915.
48. Webb CM, Elkington AG, Kraidly MM et al. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008; 101: 618–624.
49. Kapoor D, Goodwin E, Channer KS et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899–906.
50. Bhasin S. Effects of testosterone administration on fat distribution, insulin sensitivity and atherosclerosis progression. Clin Infect Dis 2003; 37 (Suppl 2): S142–S149.
51. Allan CA, Strauss BJ, Burger HG et al. Testosterone therapy prevents gain in adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008; 93: 139–146.
52. Haffner SM, Karhapää P, Mykkänen L et al. Insulin resistance, body fat distribution and sex hormones in men. Diabetes 1994; 43: 212–219.
53. Dubey RK, Oparil S, Imthurn B et al. Sex hormones and hypertension. Cardiovasc Res 2002; 53: 688–708.
54. Haffner SM, Mykkänen L, Valdez RA et al. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77: 1610–1615.